CTS™ OpTmizer™ T 细胞扩增 SFM，袋装规格
CTS™ OpTmizer™ T 细胞扩增 SFM，袋装规格
引用和文献 (5)
Gibco™

CTS™ OpTmizer™ T 细胞扩增 SFM，袋装规格

Gibco™ OpTmizer™ CTS™ T 细胞扩增 SFM 针对人 T 淋巴细胞的生长和扩增而开发。OpTmizer™了解更多信息
Have Questions?
货号数量
A10485031 袋
货号 A1048503
价格（CNY)
4,910.00
Each
添加至购物车
数量:
1 袋
价格（CNY)
4,910.00
Each
添加至购物车
Gibco™ OpTmizer™ CTS™ T 细胞扩增 SFM 针对人 T 淋巴细胞的生长和扩增而开发。OpTmizer™ CTS™ T 细胞扩增培养基是一种完全无血清和无异种成分的 1X 培养基，由 OpTmizer™ T 细胞扩增基础培养基（1 L 袋）和 OpTmizer™ T 细胞扩增补充剂 (26 mL) 组成，在使用前混合在一起。

•维持与在常规血清补充培养基中培养的 T 细胞相似的表型和功能
• 一致的性能支持 T 细胞扩增
• 支持静态和 WAVE Bioreactor™ 培养中的高密度培养物
• 使用这种按 cGmP 生产的配方和支持文件，为临床研究做好准备

通用 T 细胞培养基
OpTmizer™ CTS™ T 细胞扩增 SFM 设计用于给出与常规血清补充培养基相同的结果。然而，如果需要，可将 2% 热灭活人血清（货号 34005-100）添加至培养基，以增强活力和扩增。应根据特定 T 细胞培养应用经验确定血清的使用和所需量。

便于 T 细胞扩增
OpTmizer™ CTS™ T 细胞扩增 SFM 设计用于扩增人 T 细胞，可使 CD3+ 在静止条件下密度为 >3 x 106 个细胞/mL，WAVE 袋中密度为 >2 x 107 个细胞/mL。结果可能因 T 细胞亚群（例如，抗原特异性细胞）而异。应根据经验确定特定 T 细胞培养应用的条件。

完全培养基的稳定性
完全 OpTmizer™ CTS™ T 细胞扩增 SFM（基础、补充和 L-谷氨酰胺）在黑暗环境中于 2–8°C 下储存时可保持稳定 4 周。

简化您向临床研究的过渡
Gibco™ 细胞治疗系统 (CTS™) 品牌提供了用于细胞治疗应用的种类广泛的产品，包括培养基、试剂、生长因子、酶、细胞分选/扩增试剂和设备。Gibco™ CTS™ 产品具有以下特点：
•减少试剂验证方面的负担
• 包括适当的分析证书和原产地证明
• 方便地获得我们的药物主文件 (DMF)
规格
细胞类型T 细胞
培养环境CO2
内毒素水平极低
所含抗生素不含抗生素
无机盐钙、镁
产品类型细胞扩增无血清培养基 (SFM)
纯度或质量等级研究级
数量1 袋
分类化学成分明确, 无血清, 无异种成分
培养类型悬浮液细胞培养
形式液体
血清水平无血清
无菌无菌
加有添加剂HEPES：, 酚红, 丙酮酸钠, 碳酸氢钠
不加添加剂无谷氨酰胺
Unit SizeEach
内容与储存
OpTmizer™ T 细胞扩增基础培养基（1 x L 培养基袋）：储存在 2–8°C 下。避光储存。

OpTmizer™ T 细胞扩增补充剂 (1 x 26 mL)：在黑暗环境中于 2–8°C 下储存。

常见问题解答 (FAQ)

What is CTS?

The Gibco Cell Therapy Systems (CTS) portfolio of cell and gene therapy products are GMP manufactured, safety tested, and backed by regulatory documentation to support your transition from discovery through clinical and commercial manufacturing. Through our CTS solutions, we are committed to helping customers streamline therapeutic development, minimize risk, and ease the burden on their quality systems. Learn more here.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Do I need to order additional components with the CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503)?

The CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503) kit comes with OpTmizer T Cell Expansion Basal Medium and OpTmizer T Cell Expansion Supplement, which are mixed together prior to use. Depending on your protocol you may need to purchase T cell growth factors such as IL-2 (Cat. No. PHC0023) and L-glutamine (Cat. No. 25030) to form a complete medium. To boost growth of human T cells, human AB serum can be added. If desired, antibiotics such as Gentamicin (Cat. No. 15750), can also be added.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Will CTS OpTmizer T Cell Expansion SFM (Cat. No. A1048501, A1048502, A1048503) work with all types of T cells?

CTS OpTmizer T Cell Expansion SFM (Cat. No. A1048501, A1048502, A1048503) has been demonstrated to be effective for the ex vivo expansion of human CD3 T cells, including polyclonal T cell populations, antigen-specific T cells, tumor-infiltrating lymphocytes (TIL), cord blood T cells, regulatory T cells, T cells from HIV-infected donors, gene-modified T cells (both lenti- and MLV-based vectors), including cells of both the CD4+ and CD8+ phenotype.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Can CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503) be used for animal T cell cultures other than human?

CTS OpTmizer T Cell Expansion SFM (Cat. No. A1048501, A1048502, A1048503) has only been tested on human T cells.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Is there a difference in formulation of the CTS OpTmizer T Cell Expansion SFM between the bottle and bag packaging formats?

The bottle and bag packaging formats of the medium have the same formulation.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

View all CTS™ OpTmizer™ T 细胞扩增 SFM，袋装规格 FAQs

引用和文献 (5)

引用和文献
Abstract
Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement.
Authors:Smith C, Økern G, Rehan S, Beagley L, Lee SK, Aarvak T, Schjetne KW, Khanna R
Journal:
PubMed ID:25671129
The manufacture of clinical grade cellular products for adoptive immunotherapy requires ex vivo culture and expansion of human T cells. One of the key components in manufacturing of T cell therapies is human serum (HS) or fetal bovine serum (FBS), which can potentially expose immunotherapy recipient to adventitious infectious pathogens ... More
Bioengineering and serum free expansion of blood-derived ?d T cells.
Authors:Sutton KS, Dasgupta A, McCarty D, Doering CB, Spencer HT
Journal:Cytotherapy
PubMed ID:27260209
'Cellular immunotherapy relies on several highly variable patient-specific parameters, such as (i) cell number before and after expansion, (ii) targeting of cells to tumors, (iii) cell survival and function after infusion, and (iv) on- and off-target adverse events. Cellular approaches such as the specific expansion of ?d T cells as ... More
A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies.
Authors:Lu TL, Pugach O, Somerville R, Rosenberg SA, Kochendefer JN, Better M, Feldman SA
Journal:Hum Gene Ther Methods
PubMed ID:27897048
The treatment of B-cell malignancies by adoptive cell transfer (ACT) of anti-CD19 chimeric antigen receptor T cells (CD19 CAR-T) has proven to be a highly successful therapeutic modality in several clinical trials.(1-6) The anti-CD19 CAR-T cell production method used to support initial trials relied on numerous manual, open process steps, ... More
Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine.
Authors:Morera Y, Sánchez J, Bequet-Romero M, Selman-Housein KH, de la Torre A, Hernández-Bernal F, Martín Y, Garabito A, Piñero J, Bermúdez C, de la Torre J, Ayala M, Gavilondo JV
Journal:Vaccine
PubMed ID:28536029
CIGB-247 is a cancer therapeutic vaccine, based on recombinant modified human vascular endothelial growth factor (VEGF) as antigen, in combination with the adjuvant VSSP, a bacterially-derived adjuvant. The vaccine have demonstrated efficacy in several murine malignancy models. These studies supported the rationale for a phase I clinical trial where safety, ... More
Enhancing adoptive cancer immunotherapy with V?2Vd2 T cells through pulse zoledronate stimulation.
Authors:Nada MH, Wang H, Workalemahu G, Tanaka Y, Morita CT
Journal:J Immunother Cancer
PubMed ID:28239463
Human ?d T cells expressing V?2Vd2 T cell receptors monitor foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis to mediate immunity to microbes and tumors. Adoptive immunotherapy with V?2Vd2 T cells has been used to treat cancer patients with partial and complete remissions. Most clinical trials and preclinical studies have ... More